Document is current

Article History

Received: 2 May 2024

Accepted: 17 September 2024

First Online: 9 October 2024

Declarations

:

: This study was conducted in accordance with Good Clinical Practice (GCP) guidelines, the International Conference on Harmonization (ICH), and with the ethical principles established in the Declaration of Helsinki, the law 3301/09, and local guidelines. Personal identification data was kept anonymous. An independent ethics committee approved the protocol and the informed consent form. SAR-COVID: Approved by Claude Bernard Committee on June 8, 2020, SARCOVID.20200526.16.PI, ClinicalTrial NCT04568421; ReumaCov Brasil: Approved by Brazilian Committee of Ethics in Human Research on April 5, 2020, CAAE 30186820.2.1001.8807; number: 3.933.204, Brazilian Registry of Clinical Trials RBR-33YTQC. The GRA-COVID physician-reported registry used in CMR-COVID was determined “not human subjects’ research” by the UK Health Research Authority and the University of Manchester, as well as under United States Federal Guidelines assessed by the University of California San Francisco Institutional Review Board (). GRA-COVID protocol was approved by local ethics committee in different regions of Mexico: the Committee of Ethics in Research of the Medical Care and Research center in Yucatán, March 31st 2020; number: CONBIOÉTICA-31-CEI-003-20170920, Committee of the Research Clinic in Rheumatology and Obesity in Jalisco, Abril 9th 2020; number A579D3CB-0071-4A8C-8E80-5C06111EA2B2, Committee of Research in Humans of the Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán in Mexico City, April 16, 2020; number: IRE-3349-20-22-1, Committee of Ethics in Research of the Hospital General de México Dr. Eduardo Liceaga committee in Mexico City, May 18th 2020; number. CE/181/20.

: All patients signed the corresponding informed consent form to participate in these registries and for the publication of their data. In Mexico, participants were not required to sign an informed consent as all data was de-identified.

: MUMM: None related to this manuscript. CAI: None related to this manuscript. DAR: Employee GlaxoSmithKline Mexico unrelated to the submitted work. GJPE: None for this manuscript. BMV: None for this manuscript. MAA: None for this manuscript. IP: None related to this manuscript. RQ: None related to this manuscript. GB: None for this manuscript. MJHS: None related to this manuscript. SO: None for this manuscript. MP: None for this manuscript. IJCPP: None for this manuscript. FIP: None for this manuscript. GRC: None for this manuscript. TSRR: None for this manuscript. JAVA: None related to this manuscript. CMST: None for this manuscript. IMJM: None for this manuscript. LHS: None for this manuscript. CDLM: None related to this manuscript. RMX: None related to this manuscript. AMK: Speaker fees and/or consultancies from Organon, Abbvie, Janssen. Support for attending meetings from Abbvie and Organon. Receipt of equipments or materials from Pfizer, Abbvie and UCB. None related to this manuscript. APG: Speaker fees and/or consultancies from Janssen. Support for attending meetings from Abbvie, Janssen and Pfizer. None related to this manuscript. ETRN: Speaker fees and/or consultancies from AstraZeneca, GSK and Novartis and participation in clinical research from Abbvie, BMS and Novartis. None related to this manuscript. GSP: Speaker fees and/or consultancies from GSK, MSD, Janssen, Lilly, AstraZeneca. None related to this manuscript. GAF: Speaker fees and/or consultancies from GSK and AstraZeneca and participation in clinical research from Roche, AstraZeneca, BMS and Novartis. None related to this manuscript. LM: Speaker fees and/or consultancies from Abbvie, Novartis, Organon, Pfizer, UCB, GSK, Janssen, AstraZeneca. Support for attending meetings from Abbvie, Janssen, Pfizer, USB. None related to this manuscript. MMP: Speaker fees and/or consultancies from Novartis, Janssen, Lilly and Abbvie. None related to this manuscript. DCC: Speaker fees and/or consultancies from AstraZeneca and GSK and participation in clinical research from Roche, AstraZeneca, BMS and Novartis. None related to this manuscript.